AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00611286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel after everolimus-eluting stent implantation
Description: Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
Study NCT00438087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone administrated intra and post operatively
Study NCT00438087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: methylprednisolone administrated intra and post operatively
Study NCT02315170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular injection guide
Description: The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
Study NCT02315170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard lid speculum
Description: standard wire lid speculum
Study NCT00820157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery
Description: Cytoreductive Surgery followed by TACE for MNHCC
Study NCT00820157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE alone or TACE followed by downstage resection for MNHCC
Study NCT04427774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib plus Sintilimab
Description: Surufatinib will be given orally. Sintilimab will be given intravenously
Study NCT02716064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAP-CM Intervention
Description: The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
Study NCT04455802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine or Placebo
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
Study NCT04455802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine or Placebo
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
Study NCT04455802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine or Placebo
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
Study NCT04455802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine or Placebo
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
Study NCT02196558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Study NCT01877499 — intervention group
Intervention type: OTHER
Intervention: Optimization of HDF key parameters
Description: First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits.
Study NCT03053804 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR/PET
Description: MR/PET with contrast media and FDG-18
Study NCT03502408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
Study NCT00229970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo single injection
Study NCT01428206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liverpool care pathway
Description: Liverpool care pathway is started tha last day in life for elderly at nursing homes
Study NCT04437043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: quality of life questionnaires
Description: pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
Study NCT03502408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
Study NCT00388271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin (Xatral)
Description: standard treatment plus alfuzosin
Study NCT00388271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study NCT00734903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Woman's Path to Recovery
Description: WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
Study NCT00734903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-Step Facilitation
Description: 12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
Study NCT00877383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT00877383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
Study NCT00877383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
Study NCT00877383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix 0.25 mg.
Description: Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix 0.25 mg.
Description: Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
Study NCT00964236 — intervention group
Intervention type: DRUG
Intervention: Sapropterin
Description: Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study NCT04958720 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study NCT04958720 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy, anti-targeted agents and immunotherapy
Description: Chemotherapy, anti-targeted agents and immunotherapy
Study NCT03661983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
Study NCT03595176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Description: Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
Study NCT02828644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVO
Description: videogame-like digital therapy
Study NCT04958720 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT02725138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
Study NCT02725138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
Study NCT00914771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 pandemic Influenza vaccine 3.75µg
Description: 2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
Study NCT00914771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 pandemic Influenza vaccine 7.5µg
Description: 2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
Study NCT04105387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Tracheostomy Change
Description: The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
Study NCT02432911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)
Description: Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
Study NCT02432911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose cytarabine
Description: cytarabine 20mg bid for 10 days.
Study NCT00600665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINReportIt
Description: A pain assessment data collection tool
Study NCT00600665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAINReportIt
Description: A pain assessment data collection tool
Study NCT00600665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINUCope
Description: A multimedia patient education program tailored to the participant's SCD pain management misconceptions
Study NCT00600665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAINUCope
Description: A multimedia patient education program tailored to the participant's SCD pain management misconceptions
Study NCT00600665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAINConsultN
Description: A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
Study NCT00765830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: 50mg qd
Study NCT00765830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: qd
Study NCT05524259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol and routinely recommended folic acid
Description: Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
Study NCT05524259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Routinely recommended folic acid
Description: The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
Study NCT01145833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Treatment Group
Description: The immediate treatment group starts the 5-month treatment right after baseline assessment.
Study NCT01145833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Treatment Group
Description: The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
Study NCT00427440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 20 mg/kg
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Study NCT00427440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 10 mg/kg
Description: AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
Study NCT02923479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specific ankle rehabilitation by ARBOT device
Description: ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
Study NCT02923479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General Rehabilitation
Description: All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
Study NCT02923479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Rehabilitation
Description: All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
Study NCT02923479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specific ankle rehabilitation performed by physiotherapist
Description: Subjects in the control group underwent manually assisted range of motion exercises.
Study NCT04319861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug procedure
Description: A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
Study NCT02460120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Archimedes System
Description: The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant choriogonadotropin alfa
Description: Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant choriogonadotropin alfa
Description: Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized natural progesterone.
Description: Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
Study NCT02118051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized natural progesterone.
Description: Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
Study NCT03957304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine
Study NCT03957304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine
Study NCT02042378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Study NCT00470639 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT00470639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Study NCT01519414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01519414 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01519414 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01519414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT05871827 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative Fluoroscopic Computer Navigation
Description: Computer technology used during surgery
Study NCT00278785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: 10-20 minute brief motivational interview
Study NCT03502967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [1-13C] Pyruvate
Description: Bolus injection of study drug
Study NCT00387439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard medical treatment + anoperineal physiotherapy.
Study NCT03502967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [2-13C] Pyruvate
Description: Bolus injection of study drug
Study NCT00387439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Study NCT04380311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tacrolimus Dosing Support Tool
Description: The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
Study NCT02685748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1000 mg pd in two doses
Study NCT02685748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two pills twice a day (instead of aspirin and pantoprazole)
Study NCT02685748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40 mg/pd in two doses, for gastric protection
Study NCT00328653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine NOVA22007 0.05%
Study NCT04334720 — intervention group
Intervention type: OTHER
Intervention: Comprehensive treatment of tumor
Description: According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
Study NCT00328653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine NOVA22007 0.1%
Study NCT00328653 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Study NCT04203290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: %0.25 bupivacaine solution
Study NCT04203290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: End tidal sevoflurane concentration
Study NCT04249076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)